Treatment adherence in patients with gout

2003

Zhang, 2006, EULAR evidence-based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International clinical studies including therapeutics (ESCISIT), Ann Rheum Dis, 65, 1312, 10.1136/ard.2006.055269

Briesacher, 2008, Comparison of drug adherence rates among patients with seven different medical conditions, Pharmacotherapy, 28, 437, 10.1592/phco.28.4.437

Terkeltaub, 2009, Gout study group: update on hyperuricemia and gout, Joint Bone Spine, 76, 444, 10.1016/j.jbspin.2009.05.006

Choi, 2005, Pathogenesis of gout, Ann Intern Med, 143, 499, 10.7326/0003-4819-143-7-200510040-00009

Merriman, 2011, The genetic basis of hyperuricaemia and gout, Joint Bone Spine, 78, 35, 10.1016/j.jbspin.2010.02.027

Shoji, 2004, A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy, Arthritis Rheum, 51, 321, 10.1002/art.20405

Perez-Ruiz, 2007, Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?, Arthritis Rheum, 57, 1324, 10.1002/art.23007

Campion, 1987, Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study, Am J Med, 82, 421, 10.1016/0002-9343(87)90441-4

Jordan, 2007, British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout, Rheumatology (Oxford), 46, 1372, 10.1093/rheumatology/kem056a

Choi, 2007, Prevalence of the metabolic syndrome in individuals with hyperuricemia, Am J Med, 120, 442, 10.1016/j.amjmed.2006.06.040

Facchini, 1991, Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration, JAMA, 266, 3008, 10.1001/jama.266.21.3008

Zoppini, 2009, Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients, Diabetes Care, 32, 1716, 10.2337/dc09-0625

Choi, 2007, Independent impact of gout on mortality and risk for coronary heart disease, Circulation, 116, 894, 10.1161/CIRCULATIONAHA.107.703389

Fam, 2002, Gout, diet, and the insulin resistance syndrome, J Rheumatol, 29, 1350

Choi, 2005, Gout: epidemiology and lifestyle choices, Curr Opin Rheumatol, 17, 341

Lawrence, 2008, Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II, Arthritis Rheum, 58, 26, 10.1002/art.23176

Miao, 2008, Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China, J Rheumatol, 35, 1859

Roddy, 2008, Hyperuricemia, gout, and lifestyle factors, J Rheumatol, 35, 1689

Choi, 2010, A prescription for lifestyle change in patients with hyperuricemia and gout, Curr Opin Rheumatol, 22, 165, 10.1097/BOR.0b013e328335ef38

Bieber, 2004, Gout: on the brink of novel therapeutic options for an ancient disease, Arthritis Rheum, 50, 2400, 10.1002/art.20438

O’Duffy, 1975, Decreasing prevalence of tophaceous gout, Mayo Clin Proc, 50, 227

Falasca, 2006, Metabolic diseases: gout, Clin Dermatol, 24, 498, 10.1016/j.clindermatol.2006.07.015

Day, 2009, Adherence to urate-lowering therapy, South Med J, 102, 114, 10.1097/SMJ.0b013e31819042a0

Perez-Ruiz, 2009, Treating to target: a strategy to cure gout, Rheumatology (Oxford), 48, ii9, 10.1093/rheumatology/kep087

Harold, 2009, Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature, Semin Arthritis Rheum, 38, 396, 10.1016/j.semarthrit.2008.01.011

de Klerk, 2003, Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout, J Rheumatol, 30, 44

Riedel, 2004, Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims, J Rheumatol, 31, 1575

Sarawate, 2006, Gout medication treatment patterns and adherence to standards of care from a managed care perspective, Mayo Clin Proc, 81, 925, 10.4065/81.7.925

Harrold, 2009, Adherence with urate-lowering therapies for the treatment of gout, Arthritis Res Ther, 11, R46, 10.1186/ar2659

Harrold, 2010, The dynamics of chronic gout treatment: medication gaps and return to therapy, Am J Med, 123, 54, 10.1016/j.amjmed.2009.05.026

Halpern, 2009, Impact of non compliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis, Curr Med Res Opin, 25, 1711, 10.1185/03007990903017966

Solomon, 2008, Uric acid lowering therapy: prescribing patterns in a large cohort of older adults, Ann Rheum Dis, 67, 609, 10.1136/ard.2007.076182

Perez-Ruiz, 2002, Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout, Arthritis Rheum, 47, 356, 10.1002/art.10511

Reach, 2006

Ahmed, 2006, Alcohol consumption is inversely associated with adherence to diabetes self-care behaviours, Diabet Med, 23, 795, 10.1111/j.1464-5491.2006.01878.x

Wortmann, 2006, The management of gout: it should be crystal clear, J Rheumatol, 33, 1921

Reach, 2010, Is there an impatience genotype leading to non-adherence to long-term therapies?, Diabetologia, 53, 1562, 10.1007/s00125-010-1755-3

Reach, 2010

Reach, 2008, Patient non-adherence and healthcare-provider inertia are clinical myopia, Diabetes Metab, 34, 382, 10.1016/j.diabet.2008.02.008

Steele, 1990, Alcohol myopia. Its prized and dangerous effects, Am Psychol, 45, 921, 10.1037/0003-066X.45.8.921

Becker, 2008, We can make gout management more successful now, Curr Opin Rheumatol, 20, 167, 10.1097/BOR.0b013e3282f54d03

Mikuls, 2004, Quality of care indicators for gout management, Arthritis Rheum, 50, 937, 10.1002/art.20102

Mikuls, 2005, Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD), Rheumatology (Oxford), 44, 1038, 10.1093/rheumatology/keh679

Singh, 2007, Quality of care for gout in the US needs improvement, Arthritis Rheum, 57, 822, 10.1002/art.22767